A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
Starling, N Vázquez-Mazón, F Cunningham, D Chau, I Tabernero, J Ramos, F Iveson, T Saunders, Mark P Aranda, E Countouriotis, A
Starling, N
Vázquez-Mazón, F
Cunningham, D
Chau, I
Tabernero, J
Ramos, F
Iveson, T
Saunders, Mark P
Aranda, E
Countouriotis, A
Citations
Altmetric:
Abstract
This study evaluated the maximum tolerated dose (MTD) of sunitinib, a multitargeted tyrosine kinase inhibitor, combined with FOLFIRI (irinotecan 180 mg/m2 given over 90 min i.v. and l-leucovorin 200 mg/m2 given over 120 min on day 1, followed by 5-FU 400 mg/m2 bolus and then 2400 mg/m2 infused over 46 h) in untreated metastatic colorectal cancer (mCRC).
Description
Date
2012-01
Publisher
Collections
Keywords
Type
Article
Citation
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. 2012, 23 (1):119-27 Ann Oncol